View in EDS

Cytology and High-Risk Human Papillomavirus Testing Performance for Cervical Cancer Screening in Transmasculine Patients.

Saved in:
Bibliographic Details
Title: Cytology and High-Risk Human Papillomavirus Testing Performance for Cervical Cancer Screening in Transmasculine Patients.
Authors: Bolten, Katherine (AUTHOR), Burns, Haley (AUTHOR), Scott, Carter (AUTHOR), Smart, Kyla (AUTHOR), Mittal, Astha (AUTHOR), De Haan, Gene (AUTHOR), Jou, Jessica (AUTHOR), Bruegl, Amanda (AUTHOR)
Source: Journal of Women's Health (15409996). Jul2026, Vol. 35 Issue 7, p670-676. 7p.
Subjects: Cytology, Cervical intraepithelial neoplasia, Testosterone, Perimenopause, Hysterectomy, Cervix uteri tumors, Data analysis, Research funding, Early detection of cancer, Papillomaviruses, Postmenopause, Retrospective studies, Descriptive statistics, Longitudinal method, Colposcopy, Cisgender people, Research, Medical records, Acquisition of data, Pap test, Comparative studies, Data analysis software, Sensitivity & specificity (Statistics)
Abstract: Objective: The primary objective of this study was to estimate the specificity of cytology and high-risk human papillomavirus (hrHPV) testing to predict the presence of cervical intraepithelial neoplasia 2 (CIN2+) among transmasculine patients. The exploratory objective compared the specificity of cytology and hrHPV tests among three populations: transmasculine patients using testosterone, premenopausal cisgender, and postmenopausal cisgender patients. Design: This multicenter retrospective cohort study included individuals aged 18–65 undergoing cervical cancer screening from 2015 to 2024. Transmasculine patients were included if using ≥ 30 mg daily transdermal or ≥ 30 mg weekly subcutaneous testosterone for at least 6 months with no estrogen supplementation. Patients with co-tests followed by colposcopy or hysterectomy were included in the sensitivity and specificity analysis. McNemar's test was used to examine differences in specificity between cytology and hrHPV tests within each cohort. Results: Of 2,437 records screened, 149 (70 transmasculine, 30 postmenopausal, and 49 premenopausal) met the inclusion criteria with co-tests followed by histologic confirmation via colposcopy or hysterectomy. In the transmasculine cohort, the specificity of screening to predict CIN2+ was comparable between cytology (68.9% [95% CI: 55.7 − 80.1%]) and hrHPV tests (63.9% [95% CI: 50.6 − 75.8%]) with a p -value of 0.26. Sensitivity was equivalent in the transmasculine cohort. In the postmenopausal cohort, specificity was significantly lower for hrHPV screening compared to cytology (24.1% vs. 69.0%). Conclusions: The ability of cytology and hrHPV screening to predict the presence of CIN2 + was not different in the transmasculine population. With high insufficient cytology rates, transitioning to primary hrHPV screening can limit unwanted pelvic exams and unnecessary diagnostic testing in transmasculine patients. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Women's Health (15409996) is the property of Mary Ann Liebert, Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Objective: The primary objective of this study was to estimate the specificity of cytology and high-risk human papillomavirus (hrHPV) testing to predict the presence of cervical intraepithelial neoplasia 2 (CIN2+) among transmasculine patients. The exploratory objective compared the specificity of cytology and hrHPV tests among three populations: transmasculine patients using testosterone, premenopausal cisgender, and postmenopausal cisgender patients. Design: This multicenter retrospective cohort study included individuals aged 18–65 undergoing cervical cancer screening from 2015 to 2024. Transmasculine patients were included if using ≥ 30 mg daily transdermal or ≥ 30 mg weekly subcutaneous testosterone for at least 6 months with no estrogen supplementation. Patients with co-tests followed by colposcopy or hysterectomy were included in the sensitivity and specificity analysis. McNemar's test was used to examine differences in specificity between cytology and hrHPV tests within each cohort. Results: Of 2,437 records screened, 149 (70 transmasculine, 30 postmenopausal, and 49 premenopausal) met the inclusion criteria with co-tests followed by histologic confirmation via colposcopy or hysterectomy. In the transmasculine cohort, the specificity of screening to predict CIN2+ was comparable between cytology (68.9% [95% CI: 55.7 − 80.1%]) and hrHPV tests (63.9% [95% CI: 50.6 − 75.8%]) with a p -value of 0.26. Sensitivity was equivalent in the transmasculine cohort. In the postmenopausal cohort, specificity was significantly lower for hrHPV screening compared to cytology (24.1% vs. 69.0%). Conclusions: The ability of cytology and hrHPV screening to predict the presence of CIN2 + was not different in the transmasculine population. With high insufficient cytology rates, transitioning to primary hrHPV screening can limit unwanted pelvic exams and unnecessary diagnostic testing in transmasculine patients. [ABSTRACT FROM AUTHOR]
ISSN:15409996
DOI:10.1177/15409996261433761